The Company's 2021 consolidated financial
statements have been approved by the Board of Directors
Date of events
2022/03/25
To which item it meets
paragraph 31
Statement
1.Date of the board of directors submitted or approved:2022/03/25
2.Date of the audit committee approved:2022/03/25
3.Start and end dates of financial reports or unaudited financial
information of the reporting period(XXXX/XX/XX~XXXX/XX/XX):
2021/01/01~2021/12/31
4.Operating revenue accumulated from 1/1 to end of the period
(thousand NTD):3,850,027
5.Gross profit (loss) from operations accumulated from 1/1 to end of
the period (thousand NTD):833,956
6.Net operating income (loss) accumulated from 1/1 to end of the period
(thousand NTD):258,451
7.Profit (loss) before tax accumulated from 1/1 to end of the period
(thousand NTD):267,629
8.Profit (loss) accumulated from 1/1 to end of the period
(thousand NTD):193,428
9.Profit (loss) during the period attributable to owners of parent
accumulated from 1/1 to end of the period (thousand NTD):232,663
10.Basic earnings (loss) per share accumulated from 1/1 to end of
the period (NTD):2.04
11.Total assets end of the period (thousand NTD):6,112,808
12.Total liabilities end of the period
(thousand NTD):2,229,514
13.Equity attributable to owners of parent end of the
period (thousand NTD):3,148,802
14.Any other matters that need to be specified:None
Attachments
Original Link
Original Document
Permalink
Disclaimer
ShareHope Medicine Co. Ltd. published this content on 25 March 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 March 2022 06:15:18 UTC.
ShareHope Medicine Co., Ltd. is principally engaged in the supply of pharmaceuticals, medical materials and technology materials. The Company is also engaged in the provision of medical health check and medical testing laboratories management consulting and entrusted operation services, the leasing of equipment and the provision of long-term care services. The Company operates its business through five segments: pharmaceutical distribution, health management, technology materials, hospitals and others. The Company distributes its products within domestic market and to overseas markets.